[1]Styczynski J,Tridello G,Koster L,et al.Death after hematopoietic stem cell transplantation:changes over calendar year time,infections and associated factors[J].Bone MarrowTransplant,2020,55(1)::10.1038/s-019-0624-z.

[2]Ciurea SO,Labopin M,Socie G,et and survival after transplantation for complex karyotype acute myeloid leukemia:A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center[J].Cancer,2018,124(10)::10.1002/cncr..

[3]Piemontese S,Boumendil A,Labopin M,et relapse following unmanipulated haploidentical transplantation:a risk factor analysis on behalf of the ALWP of the EBMT[J].J Hematol Oncol,2019,12(1):68.DOI:10.1186/s-019-0751-4.

[4]Zhao XS,Liu YR,Xu LP,et residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts[J].Am J Hematol,2019,94(5)::10.1002/ajh..

[5]Scott BL,PasquiniMC,Logan BR,et Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes[J].J Clin Oncol,2017,35(11)::10.1200/

[6]Bader P,Kreyenberg H,Von Stackelberg A,et of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows forthe identification ofimpending relapse:results ofthe ALL-BFMSCT 2003 trial[J].J Clin Oncol,2015,33(11)::10.1200/

[7]Signori A,Crocchiolo R,Oneto R,et GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors[J].Bone MarrowTransplant,2012,47(11)::10.1038/

[8]Chang YJ,Wang Y,Liu YR,et allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry:a retrospective and prospective analysis[J].J Hematol Oncol,2017,10(1):134.DOI:10.1186/s-017-0502-3.

[9]Chang YJ,Wang Y,Xu LP,et donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL:a phase 3 genetically randomized study[J].J HematolOncol,2020,13(1):27.DOI:10.1186/s-020-00860-y.

[10]Luo Y,Xiao H,Lai X,et haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCTand unrelated HSCT[J].Blood,2014,124(17)::10.1182/blood-2014-04-.

[11]Malard F,Labopin M,Stuhler G,et Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate-or High-Risk Acute Myeloid Leukemia in Complete Remission:A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation[J].Biol Blood Marrow Transplant,2017,23(2)::10.1016/

[12]Middeke JM,Herbst R,Parmentier S,et salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML:results of the BRIDGE trial[J].Leukemia,2016,30(2)::10.1038/

[13]Zhang R,Shi W,Wang HF,et haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia[J].Bone Marrow Transplant,2017,52(9)::10.1038/

[14]Heinicke T,Labopin M,Schmid C,et Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission:A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J].Biol Blood Marrow Transplant,2018,24(11)::10.1016/

[15]Xiao H,Li L,Pang Y,et treatment combining cladribine-based re-induction,myeloablative allogeneic HSCT,and prophylactic donor lymphocyte infusion:a promising treatment for refractory acute myeloid leukemia[J].Ann Hematol,2018,97(12)::10.1007/s00277-018-3453-z.

[16]Yang J,Cai Y,Jiang J,et al.Early tapering of immunosuppressive agentsafter HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia[J].Ann Hematol,2018,97(3)::10.1007/s00277-017-3204-6.

[17]Schmid C,Labopin M,Schaap N,et donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia- a matched pair analysis by the Acute Leukaemia Working Party of EBMT[J].Br J Haematol,2019,184(5)::10.1111/bjh..

[18]Yan CH,Liu QF,Wu DP,et Donor Lymphocyte Infusion (DLI)Followedby Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia[J].Biol Blood Marrow Transplant,2017,23(8)::10.1016/

[19]Yang L,Tan Y,Shi J,et modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia:a matched-pair analysis[J].Bone Marrow Transplant,2020.DOI:10.1038/s-020-01088-7.

[20]Yan CH,Liu DH,Liu KY,et al.Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation[J].Blood,2012,119(14)::10.1182/blood-2011-09-.

文章来源：《中国实验血液学杂志》 网址: http://www.zgsyxyxzz.cn/qikandaodu/2021/0508/635.html